RMR Wealth Builders Raises Stock Position in Eli Lilly and Company (NYSE:LLY)

RMR Wealth Builders lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,686 shares of the company’s stock after acquiring an additional 107 shares during the quarter. RMR Wealth Builders’ holdings in Eli Lilly and Company were worth $3,618,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. American Century Companies Inc. increased its stake in shares of Eli Lilly and Company by 5.1% during the 2nd quarter. American Century Companies Inc. now owns 2,069,881 shares of the company’s stock valued at $1,874,029,000 after acquiring an additional 100,426 shares during the last quarter. Jupiter Asset Management Ltd. grew its stake in shares of Eli Lilly and Company by 2.0% during the 2nd quarter. Jupiter Asset Management Ltd. now owns 20,819 shares of the company’s stock valued at $18,849,000 after buying an additional 407 shares during the period. Y.D. More Investments Ltd acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $112,000. Achmea Investment Management B.V. raised its position in shares of Eli Lilly and Company by 0.6% in the 2nd quarter. Achmea Investment Management B.V. now owns 60,735 shares of the company’s stock worth $54,988,000 after buying an additional 364 shares during the period. Finally, Barings LLC acquired a new position in Eli Lilly and Company in the second quarter valued at $436,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LLY has been the subject of several research reports. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, January 1st. Bank of America reiterated a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Truist Financial upped their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, September 16th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,002.22.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Up 1.5 %

Shares of NYSE LLY traded up $12.17 during mid-day trading on Friday, reaching $799.39. 3,970,440 shares of the company traded hands, compared to its average volume of 3,071,054. Eli Lilly and Company has a fifty-two week low of $612.70 and a fifty-two week high of $972.53. The stock has a market cap of $758.87 billion, a PE ratio of 86.42, a price-to-earnings-growth ratio of 2.99 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The company’s fifty day moving average is $786.48 and its two-hundred day moving average is $860.65.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same quarter last year, the firm earned $0.10 earnings per share. The firm’s quarterly revenue was up 20.4% compared to the same quarter last year. On average, analysts expect that Eli Lilly and Company will post 13.18 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a $1.50 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 annualized dividend and a yield of 0.75%. Eli Lilly and Company’s payout ratio is currently 64.86%.

Eli Lilly and Company announced that its board has approved a stock repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.